After 20 years, Paratek ’s broad-spectrum antibiotic is headed to the FDA

More than two decades after it was first synthesized in a lab, omadacycline is finally being reviewed by the FDA for its potential as a broad-spectrum antibiotic. It’s a long-awaited milestone for Dr. Evan Loh, who serves as president, COO and CMO of Paratek Pharmaceuticals (NSDQ:PRTK), the company developing and commercializing omadacycline. It’s also emblematic of why so many pharmaceutical companies have pivoted away from the antibiotic space. “Most antibiotics do not become profitable until the third year after their launch,” Loh told Drug Delivery Business News. “From a big-pharma perspective, that level of delay in terms of reaching profitability – where it will actually go to their bottom line, given their overhead – it makes this space relatively less attractive.” Get the full story at our sister site, Drug Delivery Business News. The post After 20 years, Paratek’s broad-spectrum antibiotic is headed to the FDA appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Hospital Care Pharmaceuticals Wall Street Beat Biogen paratekpharmaceuticals Source Type: news